Dual valve Achromobacter endocarditis in a long-term acute care unit: a case report and review of the literature Authors: Mohamed Abdelgalil Published: 2026 ABSTRACT AbstractBackgroundAchromobacter xylosoxidans is an opportunistic, gram-negative organism that primarily affects immunocompromised individuals or those with indwelling medical devices. Although generally considered of low virulence, it has been increasingly recognized as a cause of serious infections, including infective endocarditis (IE), which is associated with significant morbidity and mortality and often poses therapeutic challenges.Case presentationWe present the case of a 69-year-old Middle Eastern woman with a complex medical history significant for coronary artery bypass grafting, end-stage renal disease requiring hemodialysis via a tunneled catheter, chronic respiratory failure secondary to tracheomalacia, atrial fibrillation, and persistent vegetative state following a prior cardiac arrest. The patient was transferred from the intensive care unit to a long-term acute care facility and subsequently developed recurrent polymicrobial bacteremia. Blood cultures repeatedly isolated Achromobacter xylosoxidans despite targeted antimicrobial therapy.Transthoracic echocardiography revealed a small mobile vegetation on the posterior mitral valve leaflet associated with mild-to-moderate mitral regurgitation. A follow-up study approximately 1 month later demonstrated new aortic valve involvement, consistent with disease progression. Despite antimicrobial therapy guided by susceptibility testing and catheter exchange, persistent bacteremia continued. Surgical intervention was deemed not feasible due to the patient's extreme frailty and high operative risk. During her clinical course, she developed ventilator-associated pneumonia secondary to multidrug-resistant Klebsiella pneumoniae, progressed to septic shock with lactic acidosis, and ultimately suffered a bradycardic arrest.DiscussionAchromobacter xylosoxidans endocarditis is a rare condition that predominantly affects immunocompromised individuals or those with intravascular devices. Effective management is challenging due to the organism's intrinsic and acquired antimicrobial resistance, the frequent persistence of bacteremia, and the potential requirement for surgical intervention. In patients for whom surgery is not a viable option, outcomes can be poor despite prolonged, targeted antimicrobial therapy.ConclusionThis case underscores the challenges of managing native valve infective endocarditis caused by Achromobacter xylosoxidans in medically fragile patients. The disease may progress despite appropriate antimicrobial therapy, particularly when surgical intervention is not feasible. Therefore, multidisciplinary evaluation and individualized management are essential in such high-risk cases.Keywords: Infective endocarditis, Antibiotic, Echocardiography, Sepsis, Valve Introduction This case report describes a patient with multiple comorbidities admitted to LTAC who developed native valve IE due to a rare organism, Achromobacter xylosoxidans, which has low virulence and is very difficult to treat when it affects the heart. Achromobacter organisms were described in 1971 and include multiple species. The most well known is A. xylosoxidans, which can cause many infections, mostly in immunocompromised patients [1]. This disease needs to be further investigated, as this bacterium has a high rate of antibiotic resistance, and owing to its rarity, there are no guidelines on how to treat it. Case presentation The patient was a 69-year-old Middle Eastern female admitted to our long-term acute care (LTAC) unit from an outside intensive care unit (ICU) with chronic respiratory failure requiring ongoing ventilatory support. Her medical history was significant for diabetes mellitus, hypertension, ischemic heart disease status post coronary artery bypass grafting (CABG) 4 years prior, end-stage renal disease (ESRD) on hemodialysis via tunneled catheter, atrial fibrillation, and persistent vegetative state. Two years prior to this admission, she presented with urosepsis and subsequently developed encephalopathy following administration of morphine (5 mg) and baclofen (80 mg) in the emergency department, requiring intubation and ICU admission. Electroencephalography was consistent with encephalopathy. During that admission, she experienced multiple cardiac arrests, and computed tomography of the brain revealed multiple infarcts, after which she remained in a persistent vegetative state. Upon admission to our LTAC unit, she remained ventilator-dependent due to chronic respiratory failure. A tracheostomy tube was initially in situ; however, previous tracheostomy attempts had been complicated by cardiac arrest and were described as technically difficult. During her stay, she was diagnosed with tracheomalacia. Subsequent tracheostomy attempts failed, and she remained dependent on endotracheal intubation. She was also noted to have gangrene of the left upper limb. Because of the prolonged duration of admission, the clinical course is presented using relative time intervals rather than exact calendar dates. However, a chronological summary of major clinical events, microbiological findings, echocardiographic studies, and antimicrobial therapy is provided in Table 1. Table 1Chronological timeline of clinical events, microbiological findings, echocardiographic studies, and antimicrobial therapyTime (relative)Clinical/diagnostic eventsMicrobiology (blood cultures)Antimicrobial therapyImaging/proceduresT = 0 (Admission to LTAC)Transfer from ICU to LTAC with chronic respiratory failure, ventilator-dependent, ESRDpolymicrobial bacteremia during early episodesEmpiric broad-spectrum IV antibiotics (for example piperacillin–tazobactam ± vancomycin)–T ≈ + several weeksRecurrent sepsis with rising inflammatory markers (CRP, WBC, intermittent PCT elevation)First repeated isolation of A. xylosoxidans from multiple blood culture setsTargeted therapy started with meropenem and trimethoprim–sulfamethoxazole according to susceptibility (renal-dosed)–T ≈ + few weeks after first Achromobacter isolationPersistent bacteremia despite therapy; ongoing sepsisBlood cultures persistently positive for A. xylosoxidansMeropenem + trimethoprim–sulfamethoxazole continued as targeted therapyFirst TTE: small mobile vegetation on posterior MV leafletT ≈ + 1 month after first TTEClinical suspicion of progression due to persistent inflammatory markers and bacteremiaRepeat blood cultures again positive for A. xylosoxidansProlonged course of targeted antibiotics continued; duration extended beyond initial 6-week plan due to progressionRepeat TTE: new mobile vegetation on AV, in addition to existing MV vegetation; no aortic root abscessAround same periodConsideration of diagnostic optimization and source control––TEE considered but not performedLater in course (following progression of IE)Recurrent sepsis episodes, worsening respiratory status, digital ischemia of fingers notedBlood cultures intermittently positive for A. xylosoxidans and other organisms during polymicrobial episodesTargeted antibiotics for IE continued (meropenem ± trimethoprim–sulfamethoxazole), dose-adjusted to renal function–Late clinical courseNew ventilator-associated pneumonia and septic deteriorationBlood and respiratory cultures: MDR K. pneumoniae causing VAPEscalation to ceftazidime–avibactam plus supportive ICU care; vasopressors and inotropes initiated–Terminal phaseRefractory septic shock–Ongoing supportive care; no further escalation possible– Chronological timeline of clinical events, microbiological findings, echocardiographic studies, and antimicrobial therapy On examination, the patient was ventilator dependent and in a vegetative state. Cardiovascular examination revealed normal first and second heart sounds with no audible murmur, rub, or gallop throughout the admission. Peripheral pulses were palpable, with no clinical signs of acute heart failure. No peripheral stigmata of infective endocarditis, including Osler nodes, Janeway lesions, or splinter hemorrhages, were observed. During her LTAC stay, the patient experienced recurrent episodes of sepsis requiring multiple prolonged courses of antimicrobial therapy. Bloodstream infections were polymicrobial. Organisms isolated during various episodes included non-Corynebacterium diphtheriae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Candida parapsilosis, Stenotrophomonas maltophilia, and Enterococcus faecalis (Table 3). Table 3Sputum culture showing extensively drug-resistant Klebsiella and its sensitivity profileOrganism isolatedKlebsiella pneumoniaeAntibioticResultMIC ValueAmoxicillin–ClavulanateResistantAmikacinResistantCefuroximeResistantCeftriaxoneResistantCeftazidimeResistantCiprofloxacinResistant ≥ 4CotrimoxazoleResistantGentamycinResistantImipenemResistantLevofloxacinResistantMeropenemResistant16Piperacillin–tazobactamResistant ≥ 128TetracyclineResistantErtapenemResistantCefepimeResistant ≥ 32CefazolinResistantCeftazidime/AvibactamResistantMIC Minimum inhibitory concentration Sputum culture showing extensively drug-resistant Klebsiella and its sensitivity profile MIC Minimum inhibitory concentration Inflammatory markers remained persistently elevated throughout admission. C-reactive protein levels fluctuated but remained consistently raised despite targeted antimicrobial therapy. White blood cell counts demonstrated persistent leukocytosis with neutrophil predominance, and procalcitonin levels were intermittently elevated, supporting ongoing systemic infection. Repeated blood cultures demonstrated persistent growth of Achromobacter xylosoxidans, which was sensitive to ceftazidime, trimethoprim–sulfamethoxazole, and meropenem (Table 2). Table 2Blood culture showing Achromobacter growth and its sensitivity profileSiteLeft hand peripheralOrganism isolatedAchromobacter xylosoxidansAntibioticResultMIC valueAmikacinResistantCeftazidimeSensitiveCiprofloxacinResistant ≥ 4CotrimoxazoleSensitiveGentamycinIntermediateImipenemResistantLevofloxacinResistantMeropenemSensitive ≤ 0.25Piperacillin–tazobactamIntermediate64TetracyclineResistantCefepimeIntermediate16MIC Minimum inhibitory concentration Blood culture showing Achromobacter growth and its sensitivity profile MIC Minimum inhibitory concentration During earlier episodes of sepsis prior to the diagnosis of infective endocarditis, antimicrobial therapy was typically administered for approximately 3 weeks per episode, guided by clinical response and culture results. Empirical broad-spectrum antibiotics were initiated during episodes of clinical deterioration and subsequently tailored according to microbiological data and susceptibility testing. Following repeated isolation of Achromobacter xylosoxidans, antimicrobial therapy was adjusted according to in vitro susceptibility testing, with meropenem and trimethoprim–sulfamethoxazole selected as targeted therapy (Table 2). Despite appropriate targeted treatment, repeated blood culture sets remained persistently positive, indicating failure of microbiological clearance. The tunneled hemodialysis catheter was considered a potential source of persistent bacteremia and was exchanged as part of source-control measures. However, subsequent blood cultures again demonstrated growth of Achromobacter xylosoxidans, suggesting an ongoing intravascular source rather than isolated catheter-related bloodstream infection. Following echocardiographic confirmation of infective endocarditis, a 6-week course of targeted antimicrobial therapy was initiated in accordance with standard treatment principles for infective endocarditis. This course was subsequently extended when follow-up imaging demonstrated new aortic valve involvement, indicating disease progression. Despite prolonged therapy, sustained microbiological clearance was not achieved. All antimicrobial dosing was adjusted according to renal function. Given persistently elevated inflammatory markers and failure of microbiological clearance despite appropriate antimicrobial therapy, transthoracic echocardiography (TTE) was performed after discussion with the infectious diseases team. The initial TTE demonstrated a small mobile vegetation attached to the posterior leaflet of the mitral valve (Fig. 1), with associated mild-to-moderate mitral regurgitation and no evidence of aortic root abscess or severe valvular dysfunction. A repeat TTE approximately 1 month later demonstrated a new mobile vegetation on the aortic valve (Fig. 2), indicating disease progression. There was no evidence of aortic root abscess. Echocardiogram showing vegetation on the mitral valve leaflet 5-chamber view showing aortic valve vegetation Transesophageal echocardiography (TEE) was considered; however, it was not performed due to the patient’s critical illness, severe tracheomalacia, ventilator dependence, poor neurological status, and high procedural risk. The case was discussed in a multidisciplinary team meeting including infectious diseases and cardiology specialists. Due to extreme frailty, multiple comorbidities, ventilator dependence, and poor neurological status, the patient was deemed not to be a surgical candidate for valve intervention. The decision was made to continue medical management. She remained in the LTAC unit undergoing regular hemodialysis sessions. She experienced recurrent bloodstream infections and multiple episodes of ventilator-associated pneumonia (VAP), predominantly due to multidrug-resistant Klebsiella pneumoniae (Table 3). Subsequently, the patient developed ventilator-associated pneumonia secondary to multidrug-resistant Klebsiella pneumoniae. Antimicrobial therapy was escalated according to susceptibility testing, including the initiation of ceftazidime–avibactam. Despite escalation and supportive management, septic shock progressed and proved refractory to treatment. Ultimately, the patient developed septic shock secondary to ventilator-associated pneumonia, requiring increasing oxygen support and escalating vasopressor and inotropic support. The patient developed severe lactic acidosis and subsequently suffered bradycardic cardiac arrest, from which resuscitation was unsuccessful. Discussion Our case describes an elderly woman with a history of post cardiac arrest, a vegetative state, chronic respiratory failure with tracheomalacia, and ESRD. The patient continued to have persistent bacteremia with increased inflammatory markers, and a blood culture revealed Achromobacter xylosoxidans. An echocardiogram revealed vegetation on the MV, which later spread to the AV. The diagnosis of infective endocarditis was established using the modified Duke criteria. Major criteria fulfilled included persistent positive blood cultures for Achromobacter xylosoxidans and echocardiographic evidence of valvular vegetations. Minor criteria included the presence of a tunneled intravascular hemodialysis catheter, vascular phenomena (digital ischemia), and persistently elevated inflammatory markers. The combination of these findings satisfied the definition of definite infective endocarditis. This may be the first case of double-valve endocarditis caused by Achromobacter xylosoxidans. The patient was deemed too frail to undergo cardiac surgery because of her multiple comorbidities and immunocompromised state, so she is still receiving antibiotic therapy. Interestingly, our case did not have fever despite it being a common sign in nearly all the cases mentioned in the literature review and a main feature of IE overall. She also developed digital ischemia of the fingers. Although septic embolization was considered, ischemia was likely multifactorial. Contributing factors may have included severe septic shock, vasopressor exposure, prolonged critical illness, and underlying vascular disease. A definitive embolic etiology could not be confirmed. However, neurological complications could not be assessed clinically, as the patient already had a low GCS. Notably, both the AV and the MV were affected, which was observed in only a few cases. Achromobacter xylosoxidans is an aerobic, motile, oxidase-positive, gram-negative, non-fermenting rod belonging to the order Burkholderiales. It is usually found in aquatic environments [1]. It was previously known as Alcaligenes xylosoxidans before the name was changed to Achromobacter xylosoxidans. It has been named xylosoxidans because of its ability to oxidize xylose and glucose easily [2]. It was first described after being grown from cultures of patients with purulent otitis media in 1971 by Yabuuchi and Ohyama. The genus Achromobacter has multiple subspecies: xylosoxidans, ruhlandii, piechaudii, denitrificans, spanius, insolitus, and marplatensis. The most clinically significant subspecies are Achromobacter xylosoxidans and denitrificans [3]. Achromobacter xylosoxidans is a low-virulence organism, but it has the potential to cause significant disease, especially in immunocompromised hosts or those with prosthetic devices [4]. Contaminated intravenous lines are considered a common risk factor for developing Achromobacter xylosoxidans, with the other causes being mechanical ventilation and incubation. The infection is predominantly hospital-acquired, with community-acquired infections observed more often in patients with cystic fibrosis. It usually manifests as bacteremia. Polymicrobial bacteremia is observed in 28% of cases and is mostly accompanied by coagulase-negative Staphylococcus [5]. The most common clinical spectrum of Achromobacter xylosoxidans infection includes bacteremia, pneumonia, biliary tract infection, urinary tract infection, wound infection, and peritonitis [6]. One of the rare and difficult-to-treat presentations is IE, termed Achromobacter xylosoxidans endocarditis. Tokuyasu et al. reported only 11 cases of Achromobacter xylosoxidans with a confirmed diagnosis. They were all reported between 1981 and 2011. The most common predisposing conditions are associated with cardiac surgery, such as ventricular septal defect patch closure and valve replacement, and post-surgery chronic intravenous access also plays a role [7]. De Castro et al. reported that until 2020, only 20 cases of Achromobacter xylosoxidans IE were reported, with two of the cases occurring in a native valve. Our case here may be the third such case if no new cases have been reported [8]. Nosocomial IE occurs within 72 h of hospital admission or 8 weeks following an invasive operation. Some authorities support monitoring for hospital-acquired infectious endocarditis for 6 months after diagnosis. Five of the patients took almost half a year to reach the diagnosis, while 4 of them were diagnosed during autopsy [4]. Blood cultures and echocardiography are essential for the diagnosis of IE. However, clinical confirmation remains a challenge for clinicians. Duke's criteria rely on strict clinical, microbiological, and echocardiographic findings in parallel. The criteria have a specificity and negative predictive value of 99% and 92%, respectively [7]. Although Duke's criteria have been used for years to reach a diagnosis, it is often difficult to diagnose IE in clinical practice, especially if antibiotics are being used for bacteremia without vegetation. Newer modalities for the diagnosis of IE include positron emission tomography–computed tomography (PET-CT), which is more sensitive than the modalities currently in use [4]. Musculoskeletal involvement has been described previously in IE, yet it is uncommon to find patients presenting with spondylodiscitis and IE. When these conditions occur together, Streptococcus species are usually the common cause. Interestingly, the first case of septic pericarditis and pyothorax due to Achromobacter xylosoxidans was reported recently in veterinary medicine in an immunocompromised dog [9]. One of the interesting presentations described by Ahn et al. is a case of pacemaker lead endocarditis. In this scenario, the case was managed by removing the pacemaker electrode. However, a prolonged antibiotic course was recommended before and after electrode removal [10]. Achromobacter xylosoxidans is characterized by sensitivity to ceftazidime, extended-spectrum penicillin, sulfonamides, and carbapenems, with susceptibility to quinolones being variable. Colistin susceptibility was recently added to the list. Antibiotic susceptibility patterns for Achromobacter xylosoxidans include resistance to aminoglycosides, narrow-spectrum penicillins, first- and second-generation cephalosporins, certain third-generation cephalosporins (cefotaxime and ceftriaxone), and aztreonam. Despite a high resistance level to aminoglycosides, in vitro studies suggest a synergistic effect when gentamicin is added to trimethoprim/sulfamethoxazole [4]. Two main mechanisms of the intrinsic resistance of Achromobacter xylosoxidans to antibiotics have been described: multidrug efflux pumps and beta-lactamase-type chromosomal OXA-114. Antibiotic therapy is therefore a challenge, and a combination of antibiotics is most often used. However, some new antibiotics, such as cefiderocol (a new-generation cephalosporin) and eravacycline (a new tetracycline that is stable against efflux pumps), have been used in a few cases as rescue treatments [11]. La Bella et al. described a case of Achromobacter xylosoxidans native aortic valve (AV) endocarditis that was successfully treated with cefiderocol-based therapy. This was the 17th case of native AV endocarditis and the first to be successfully treated with cefiderocol therapy without the need for surgery. Our case here is also unique, as it involves both mitral valve (MV) and AV [2]. Cefiderocol is known for its activity against biofilm-forming gram-negative bacteria; this is an advantage, as a recent report showed that it can reduce biofilm formation. Cefiderocol is a viable alternative for salvage therapy of Achromobacter xylosoxidans infective endocarditis (IE) in cases where surgery is not possible [2]. As the disease itself is rare, there are no guidelines on the optimal treatment options, but antipseudomonal penicillins and carbapenems are the best choices [8]. The literature has also shown that treatment employing both antibiotics and surgical intervention is associated with a decrease in mortality compared with antibiotics alone, reinforcing the importance of early surgical consultation for possible interventions [12]. Reported mortality rates in Achromobacter xylosoxidans infective endocarditis are high, particularly among elderly and immunocompromised patients. However, outcomes are strongly influenced by overall clinical status, comorbidities, and the feasibility of surgical intervention. In our patient, the clinical course was complicated by recurrent nosocomial infections and progressive multiorgan dysfunction, and mortality cannot be attributed solely to infective endocarditis. Managing IE caused by Achromobacter xylosoxidans can be quite difficult and often requires both antibiotics and surgery. Surgical intervention, while associated with improved outcomes, is frequently contraindicated due to patient frailty and comorbidities, necessitating alternative therapies such as newer antibiotics (for example cefiderocol). Given the high mortality rate observed (> 50%) and the diagnostic difficulty, heightened clinical suspicion and comprehensive management strategies are essential for improving prognosis in such cases. Conclusion Achromobacter xylosoxidans is a rare but increasingly recognized etiology of infective endocarditis (IE), primarily affecting immunocompromised individuals or those with prosthetic devices. This case is noteworthy as it represents a possible first report of double-valve (mitral and aortic) endocarditis caused by this pathogen in the absence of fever. Key features of this presentation include persistent bacteremia, septic embolic events such as digital ischemia, and complexities in clinical evaluation in patients with impaired consciousness. The organism's intrinsic multidrug resistance and the resultant limited antimicrobial options pose significant therapeutic challenges, often necessitating prolonged antibiotic regimens, potentially in conjunction with surgical intervention. Although surgical intervention is associated with improved outcomes, it is frequently contraindicated due to patient frailty and comorbidities, thus necessitating consideration of alternative therapeutic strategies, such as newer antimicrobial agents (for example cefiderocol). Given the significant mortality rates reported in the literature and the diagnostic challenges associated with this infrequent pathogen, a high index of clinical suspicion and comprehensive, multidisciplinary management are crucial to optimizing patient outcomes. This case contributes valuable insights to the limited existing literature on Achromobacter xylosoxidans endocarditis, underscoring the importance of early recognition, even in the context of atypical clinical presentations. Acknowledgements Not applicable. Abbreviations Infective endocarditis Coronary artery bypass graft End-stage renal disease Intensive care unit Long-term acute care Hemodialysis Infectious Diseases/Infectious Disease Consultant Mitral valve Aortic valve Ventilator-associated pneumonia Ischemic heart disease Emergency room Glasgow coma scale Positron emission tomography–computed tomography Minimum inhibitory concentration Mohamed Abdelgalil is a young physician with experience in intensive care medicine and internal medicine. He holds the membership of the royal college of physicians of the United Kingdom (MRCP-UK). He is pursuing his European diploma in intensive care medicine (EDIC) as well. He is interested in publishing rare cases. He is working as a peer reviewer for journals also. Author contributions Mohamed Abdelgalil contributed to the conception, design, and writing of the manuscript in its entirety. Funding No funding was received for this work. Data availability All data generated or analyzed during this case report are included in this published article. Declarations Ethics approval and consent to participate Ethical approval for this case report was obtained from the relevant institutional review board. Written informed consent for participation was also obtained from the patient’s legal guardian. Consent for publication Written informed consent was obtained from the patient’s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The author declares no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analyzed during this case report are included in this published article.